Vimarsana
Biggest News Aggregation in the World

Page 2 - Jonathan Silverberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Silverberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Silverberg Today - Breaking & Trending Today

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards - Vimarsana News

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer-- Industry veterans and leading academic experts ...

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer ... - Vimarsana News

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer ...

-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer

Upadacitinib Can Significantly Improve Clinical Outcomes in Patients With Atopic Dermatitis - Vimarsana News

Upadacitinib Can Significantly Improve Clinical Outcomes in Patients With Atopic Dermatitis

Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

Jonathan Silverberg, MD, PhD: New Phase 3 Findings on Nemolizumab for Atopic Dermatitis - Vimarsana News

Jonathan Silverberg, MD, PhD: New Phase 3 Findings on Nemolizumab for Atopic Dermatitis

This interview at AAD featured a discussion with Silverberg on nemolizumab’s efficacy and safety at Week 48 among patients with moderate-to-severe atopic dermatitis.

Dr Jonathan Silverberg Discusses Findings on the Safety, Efficacy of Nemolizumab at 48 Weeks - Vimarsana News

Dr Jonathan Silverberg Discusses Findings on the Safety, Efficacy of Nemolizumab at 48 Weeks

In patients with moderate to severe atopic dermatitis, nemolizumab demonstrated good durability of response, explained Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences.

Source: ajmc.com